Financial Data and Key Metrics Changes - Total revenues increased to $13 million in Q4 2025 from $11.9 million in Q4 2024, representing a 10% increase primarily driven by manufacture and supply revenue growth [17][18] - Full year 2025 total revenues decreased to $44.5 million from $57.6 million in 2024, a decline of 3% when excluding one-time recognition of deferred revenues [18][26] - Net loss for Q4 2025 was $31.9 million or $0.26 per share, compared to a net loss of $17.1 million or $0.19 per share in Q4 2024 [24][26] - Full year 2025 net loss was $83.8 million or $0.78 per share, compared to a net loss of $44.1 million or $0.51 per share in 2024 [26] Business Line Data and Key Metrics Changes - Manufacture and supply revenue for the full year 2025 increased to $40.2 million from $40 million in 2024, driven by increases in Ondif revenues, partially offset by decreases in Suboxone revenues [18][19] - R&D expenses decreased to $3.2 million in Q4 2025 from $4.9 million in Q4 2024, primarily due to lower clinical trial costs associated with Anaphylm [19][20] - Selling, general and administrative expenses increased to $32.8 million in Q4 2025 from $16 million in Q4 2024, largely due to higher legal expenses and commercial spending [21][23] Market Data and Key Metrics Changes - The overall allergy market grew by just over 9% in Q4 2025, with EpiPen and generic auto injectors growing by approximately 5% [12] - Over 90% of prescriptions remain with auto-injectors, indicating a strong market preference for medical devices [12] Company Strategy and Development Direction - The company is focused on launching Anaphylm, the first oral epinephrine product, with plans to resubmit the NDA in Q3 2026 [6][10] - A significant increase in the sales force is planned, with 75 sales representatives at launch compared to the previous guidance of 50, aimed at deeper market penetration [11][41] - The company is also pursuing licensing opportunities for Libervant in the U.S. and internationally for Anaphylm, indicating a strategic focus on out-licensing [14][28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing a clear path to market for Anaphylm and a strong clinical team to support development [6][10] - The company anticipates total revenue of $46 million to $50 million for 2026, with a non-GAAP adjusted EBITDA loss of $30 million to $35 million [28][29] - Management highlighted the importance of capital access for the launch of Anaphylm, with RTW extending their revenue sharing agreement and investing additional capital [12][17] Other Important Information - The company reached a settlement in a long-standing defamation lawsuit, which is expected to reduce distractions from the business [13] - The company has opened an IND for AQST-108 and completed dosing of the initial safety study, with top-line clinical data expected soon [15] Q&A Session Summary Question: Confirmation of Type A meeting with the FDA - The company confirmed that a request for a Type A meeting has been submitted and is expected to occur within 30 days [31][32] Question: Goals for the upcoming FDA meeting - The company aims to ensure alignment on executing the requested studies and has prepared a briefing book for the FDA [32][33] Question: Details on the modification to the proposed protocol - The modification is considered minor, and the company is prepared to discuss it with the FDA [34] Question: Timing of the RTW agreement extension - The extension until June 30, 2027, is a buffer and does not indicate a delay in product launch [38] Question: Rationale for increasing sales representatives - The increase is driven by the need for deeper market penetration and greater efficiency in reaching physicians [41][42] Question: Future clinical development of AQST-108 - The development of AQST-108 will be prioritized after the Anaphylm resubmission, but both projects will progress concurrently [84][85]

Company Overview - Aquestive Therapeutics is a publicly traded pharmaceutical company (NASDAQ: AQST) focused on advancing medicines through innovative science and delivery technologies[7] - The company has shipped over 25 billion PharmFilm doses worldwide[10] - Aquestive Therapeutics reported over $57 million in revenue in 2024[13, 14] - The company anticipates 2 product launches in the U S by 2027[17] - The company estimates over $15 billion in potential peak annual net sales from pipeline assets[18] Anaphylm (epinephrine) Sublingual Film - The U S epinephrine market has the potential to grow to approximately $2 billion in value by 2031[54] - The current market size in 2024 is approximately $800 million[55] - The epinephrine market has experienced a 15% CAGR from 2021 to 2023[55, 56] - 95% of patients are interested in a film-dosing option for epinephrine[66] - The PDUFA action date for Anaphylm is scheduled for January 31, 2026[27, 69] AQST-108 (epinephrine) Topical Gel - The company is pursuing alopecia areata (AA) as a potential initial indication for AQST-108[75] - The market opportunity for JAK inhibitors for alopecia areata is estimated at over $1 billion[80]